Sirolimus for lymphatic-venous malformation
Reviewed by Hetvi Bhatt

This is a case report on the use of oral sirolimus in the treatment of lymphatic-venous malformations. This condition can often be sight-threatening when present in the orbit and traditional management options have included observation, sclerotherapy and surgery. Both sclerotherapy and surgery have significant risks due to difficult access, risk of recurrence and loss of sight. Access to centres that provide sclerotherapy can also be difficult as, in the UK, it is a service that is limited to specialised centres. The authors report the use of sirolimus (an mTOR inhibitor) at 4mg/day with minimal side-effects. One limiting factor is that the length of treatment required is unknown and often patients will require being on the medication for long periods.

Intraorbital lymphatic-venous malformation in an adult patient: is sirolimus the key?
Santacruz ARV, Pascual IN, Canorea PC, et al.
ORBIT
2024;4(2):535–8.